The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Extrafine single inhaler triple therapy is effective among patients with COPD who were previously treated with multiple-inhaler triple therapy.

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while ...

Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In the 7MM ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...